$798 Million is the total value of Rhenman & Partners Asset Management AB's 93 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 8.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVCR | Sell | NovoCure Ltd Reg | $25,425,000 | +9.9% | 340,000 | -7.1% | 3.19% | +25.1% |
| JAZZ | Sell | Jazz Pharmaceuticals Plc | $19,221,000 | -28.0% | 150,000 | -19.9% | 2.41% | -18.0% |
| CVS | Sell | CVS Health Corp | $19,159,000 | +2.3% | 303,768 | -11.6% | 2.40% | +16.4% |
| ABT | Sell | Abbott Laboratories | $18,417,000 | -15.6% | 220,114 | -15.2% | 2.31% | -4.0% |
| LLY | Sell | Eli Lilly & Co | $16,775,000 | -5.4% | 150,000 | -6.2% | 2.10% | +7.7% |
| UNH | Sell | United Health Group Inc | $16,734,000 | -34.7% | 77,000 | -26.7% | 2.10% | -25.7% |
| BDX | Sell | Becton Dickinson & Co | $15,936,000 | -21.0% | 63,000 | -21.2% | 2.00% | -10.0% |
| HUM | Sell | Humana Inc | $15,340,000 | -44.9% | 60,000 | -42.9% | 1.92% | -37.3% |
| BSX | Sell | Boston Scientific Corp | $15,055,000 | -9.7% | 370,000 | -4.6% | 1.89% | +2.8% |
| ANTM | Sell | Anthem Inc | $14,406,000 | -43.3% | 60,000 | -33.3% | 1.81% | -35.5% |
| GKOS | Sell | Glaukos Corp | $14,352,000 | -19.3% | 229,600 | -2.7% | 1.80% | -8.2% |
| NBIX | Sell | Neurocrine Biosciences Inc | $13,480,000 | -11.3% | 149,600 | -16.9% | 1.69% | +1.0% |
| CI | Sell | Cigna Corp Reg | $12,143,000 | -19.9% | 80,000 | -16.8% | 1.52% | -8.8% |
| IMMU | Sell | Immunomedics Inc | $11,271,000 | -4.5% | 850,000 | -0.2% | 1.41% | +8.6% |
| FGEN | Sell | FibroGen Inc | $10,909,000 | -30.5% | 295,000 | -15.1% | 1.37% | -20.9% |
| MYOK | Sell | MyoKardia Inc Reg | $10,430,000 | -7.6% | 200,000 | -11.1% | 1.31% | +5.2% |
| MGNX | Sell | Macrogenics Inc | $10,200,000 | -29.9% | 799,373 | -6.7% | 1.28% | -20.2% |
| XNCR | Sell | Xencor Inc | $10,204,000 | -22.0% | 302,523 | -5.4% | 1.28% | -11.3% |
| IOVA | Sell | Iovance Biotherapeutics Inc Reg | $9,464,000 | -48.6% | 520,000 | -30.7% | 1.19% | -41.5% |
| HCA | Sell | HCA Healthcare Inc | $9,032,000 | -50.9% | 75,000 | -44.9% | 1.13% | -44.2% |
| LIVN | Sell | Livanova Plc | $8,855,000 | -18.0% | 120,000 | -20.0% | 1.11% | -6.6% |
| ABC | Sell | AmerisourceBergen Corp | $8,151,000 | -32.4% | 99,000 | -30.0% | 1.02% | -23.1% |
| MRTX | Sell | Mirati Therapeutics Inc Reg | $7,791,000 | -58.4% | 100,000 | -45.1% | 0.98% | -52.7% |
| MDCO | Sell | Medicines Co | $7,650,000 | +4.9% | 153,000 | -23.5% | 0.96% | +19.4% |
| CNC | Sell | Centene Corp | $7,571,000 | -51.1% | 175,000 | -40.7% | 0.95% | -44.3% |
| ARNA | Sell | Arena Pharmaceuticals Inc Reg | $7,094,000 | -28.8% | 155,000 | -8.8% | 0.89% | -19.0% |
| SGMO | Sell | Sangamo Therapeutics Inc Reg | $6,650,000 | -22.2% | 734,811 | -7.4% | 0.83% | -11.5% |
| OMCL | Sell | Omnicell Inc | $6,504,000 | -24.7% | 90,000 | -10.3% | 0.82% | -14.3% |
| ITCI | Sell | Intra-Cellular Therapies Inc | $6,350,000 | -48.5% | 850,000 | -10.5% | 0.80% | -41.4% |
| CHRS | Sell | Coherus BioSciences Inc | $5,875,000 | -31.8% | 290,000 | -25.6% | 0.74% | -22.4% |
| EXEL | Sell | Exelixis Inc | $5,659,000 | -42.4% | 320,000 | -30.4% | 0.71% | -34.5% |
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $5,549,000 | -6.2% | 69,000 | -15.4% | 0.70% | +6.7% |
| DPLO | Sell | Diplomat Pharmacy Inc Reg | $5,194,000 | -29.1% | 1,060,000 | -11.9% | 0.65% | -19.3% |
| BLUE | Sell | Bluebird Bio Inc | $4,775,000 | -46.4% | 52,000 | -25.7% | 0.60% | -38.9% |
| EPZM | Sell | Epizyme Inc Reg | $4,642,000 | -25.1% | 450,028 | -8.8% | 0.58% | -14.7% |
| RIGL | Sell | Rigel Pharmaceuticals Inc | $3,740,000 | -36.7% | 2,000,000 | -11.7% | 0.47% | -28.0% |
| HMSY | Sell | HMS Holdings Corp Reg | $3,388,000 | +4.6% | 98,300 | -1.7% | 0.42% | +19.0% |
| SAGE | Sell | Sage Therapeutics Inc | $2,806,000 | -29.2% | 20,000 | -7.6% | 0.35% | -19.3% |
| MDGL | Sell | Madrigal Pharmaceuticals Inc Reg | $2,587,000 | -33.7% | 30,000 | -19.4% | 0.32% | -24.7% |
| RVNC | Sell | Revance Therapeutics Inc | $2,261,000 | -9.8% | 173,917 | -10.0% | 0.28% | +2.5% |
| VRAY | Sell | ViewRay Inc Reg | $1,843,000 | -68.5% | 635,434 | -4.3% | 0.23% | -64.1% |
| VKTX | Sell | Viking Therapeutics Inc Reg | $1,376,000 | -43.1% | 200,000 | -31.4% | 0.17% | -35.3% |
| ONCE | Exit | Spark Therapeutics Inc | $0 | – | -10,000 | -100.0% | -0.11% | – |
| QGEN | Exit | Qiagen NV Reg | $0 | – | -60,000 | -100.0% | -0.27% | – |
| INCY | Exit | Incyte Corp Ltd | $0 | – | -100,000 | -100.0% | -0.94% | – |
| HBNC | Exit | Horizon Therapeutics Plc | $0 | – | -1,087,656 | -100.0% | -2.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-10-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.